이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Ascendis Pharma 과거 수익 실적

과거 기준 확인 0/6

Ascendis Pharma의 수입은 연평균 -21.7%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 12.4%의 비율로 증가했습니다. 매출은 연평균 72.7%의 비율로 증가해 왔습니다.

주요 정보

-21.7%

수익 성장률

-17.5%

EPS 성장률

Biotechs 산업 성장	12.9%
매출 성장률	72.7%
자기자본 수익률	n/a
순이익	-152.4%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Ascendis Pharma 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

BMV:ASND N 수익, 비용 및 수입 (EUR Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	329	-502	265	378
31 Dec 23	267	-481	264	413
30 Sep 23	152	-602	257	431
30 Jun 23	119	-609	254	417
31 Mar 23	78	-569	240	403
31 Dec 22	51	-583	221	380
30 Sep 22	33	-482	213	337
30 Jun 22	19	-393	192	298
31 Mar 22	14	-446	170	291
31 Dec 21	8	-384	160	296
30 Sep 21	3	-416	132	491
30 Jun 21	5	-458	111	432
31 Mar 21	5	-418	96	349
31 Dec 20	7	-419	77	261
30 Sep 20	9	-360	73	50
30 Jun 20	8	-264	66	192
31 Mar 20	10	-228	56	140
31 Dec 19	13	-218	48	192
30 Sep 19	21	-170	40	179
30 Jun 19	19	-178	37	70
31 Mar 19	16	-142	31	161
31 Dec 18	11	-130	25	140
30 Sep 18	0	-132	21	130
30 Jun 18	1	-132	17	128
31 Mar 18	1	-140	15	110
31 Dec 17	2	-124	13	100
30 Sep 17	2	-106	13	92
30 Jun 17	3	-91	12	79
31 Mar 17	4	-73	12	70
31 Dec 16	5	-69	12	66
30 Sep 16	6	-64	12	59
30 Jun 16	6	-53	10	50
31 Mar 16	7	-55	10	49
31 Dec 15	8	-33	9	41
30 Sep 15	9	-26	8	36
30 Jun 15	10	-21	8	31
31 Mar 15	12	-8	8	23
31 Dec 14	14	-10	6	20
30 Sep 14	17	-2	4	15
30 Jun 14	20	0	3	15
31 Mar 14	20	3	3	13
31 Dec 13	20	4	2	13

양질의 수익: ASND N 은(는) 현재 수익성이 없습니다.

이익 마진 증가: ASND N 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: ASND N 은(는) 수익성이 없으며 지난 5년 동안 연간 21.7% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 ASND N 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: ASND N 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -2.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: ASND N 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

Ascendis Pharma 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Ascendis Pharma A/S to Report Fiscal Year 2022 Results on Feb 16, 2023

Third quarter 2022 earnings released: €3.03 loss per share (vs €1.47 loss in 3Q 2021)

Second quarter 2022 earnings released: €1.46 loss per share (vs €2.50 loss in 2Q 2021)

Recent updates

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Ascendis Pharma A/S Introduces Vision 2030

New minor risk - Profitability

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

New major risk - Negative shareholders equity

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Aendis Pharma A/S Reports One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

Ascendis Pharma Showcases its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

Ascendis Pharma A/S to Report Fiscal Year 2022 Results on Feb 16, 2023

Ascendis Pharma A/S Announces U.S. Food & Drug Administration Allows to Initiate an Expanded Access Program for Its Investigational Parathyroid Hormone Replacement Therapy, Transcon PTH

Ascendis Pharma Submits Marketing Authorization Application to the European Medicines Agency for Transcon™ PTH in Adult Patients with Hypoparathyroidism

TransCon CNP Achieves Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022

Third quarter 2022 earnings released: €3.03 loss per share (vs €1.47 loss in 3Q 2021)

Ascendis Pharma A/S Announces FDA Accepts for Priority Review Its NDA for TransCon(TM) PTH in Adult Patients with Hypoparathyroidism

Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for TranscendIT-101, A Phase 1/2 Clinical Trial of TransCon TLR7/8 Agonist in Solid Tumors

Ascendis Pharma A/S Appoints William Carl Fairey Jr. and Siham Imani as Class I Directors

Ascendis Pharma A/S announces new Week 110 data from the Phase 2 PaTH Forward Trial

Ascendis Pharma Submits Transcon™ Pth New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism

Second quarter 2022 earnings released: €1.46 loss per share (vs €2.50 loss in 2Q 2021)

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기